Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]
Leuk Res. 2017 Aug:59:65.
doi: 10.1016/j.leukres.2017.02.007.
Epub 2017 May 30.
1 Leukemia Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, FL, United States. Electronic address: rswords@med.miami.edu.
2 Stanford Cancer Institute, Stanford, CA, United States.
3 The Alfred Hospital and Monash University, Melbourne, Australia.
4 The Royal Brisbane and Women's Hospital, Brisbane, Australia.
5 Cleveland Clinic, Cleveland, OH, United States.
6 Westmead Hospital, Westmead, Australia.
7 The Royal Adelaide Hospital, Adelaide, Australia.
8 The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
9 Leukemia Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, FL, United States.
10 KaloBios Pharmaceuticals, Inc., South San Francisco, CA, United States.
11 H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.